Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
This study has been completed.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by (Responsible Party):
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00716417
First received: July 15, 2008
Last updated: January 19, 2012
Last verified: January 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study to determine the maximum tolerated dose of BIBW 2992 when combined with backbone chemotherapies consisting in cisplatin plus paclitaxel or cisplatin plus 5 FU.
The overall safety, the pharmacokinetics and the anti-tumour efficacy will also be assessed.
| Condition | Intervention | Phase |
|---|---|---|
|
Neoplasms |
Drug: BIBW 2992 Drug: BIBW 2992 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase Ib Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Continuous Dosing With BIBW 2992 Combined With Two Different Regimens of Backbone Chemotherapy: Cisplatin Combined With 5 Fluorouracil and Cisplatin Combined With Paclitaxel in Patients With Advanced Solid Tumors. |
Resource links provided by NLM:
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Primary Outcome Measures:
- To define MTDA and MTDB of BIBW 2992 when combined with cisplatin/paclitaxel or cisplatin/5-FU as assessed during the first cycle. [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Incidence and intensity of adverse events according to Common Toxicity Criteria (CTCAE v.3.0) associated with increasing doses of BIBW 2992 in combination with I.V. administration of cisplatin with either paclitaxel or 5-FU. [ Time Frame: from 1st treatment until EOT ] [ Designated as safety issue: No ]
- Pharmacokinetic and pharmacodynamic parameters of BIBW 2992 in combination with I.V. cisplatin and paclitaxel or cisplatin and 5-FU. [ Time Frame: from 1st treatment until EOT ] [ Designated as safety issue: No ]
- Objective tumour response based on RECIST criteria. [ Time Frame: from 1st treatment until EOT ] [ Designated as safety issue: No ]
| Enrollment: | 47 |
| Study Start Date: | July 2008 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A. BIBW 2992-cisplatin-paclitaxel
daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
|
Drug: BIBW 2992
low to high dose, daily
|
|
Experimental: B. BIBW 2992-cisplatin-5FU
daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
|
Drug: BIBW 2992
In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Patients with histologically or cytologically confirmed diagnosis of non resectable and / or metastatic cancer, preferably squamous cell carcinomas of head and neck, oesophagus, lung or cervix
- Indication for a standard treatment with either cisplatin plus paclitaxel or cisplatin plus 5 FU as judged by the investigator
- Age 18 years or older.
- Life expectancy of at least three (3) months.
- Written informed consent that is consistent with ICH-GCP guidelines.
- Eastern Cooperative Oncology Group (ECOG) performance score less or equal 2.
- Patients must have recovered from any therapy-related toxicity from previous chemo-, hormone-, immuno-, or radiotherapies.
- Patients recovered from previous surgery.
Exclusion criteria:
- Active infectious disease.
- Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea.
- Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
- Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least four (4) weeks, no history of cerebral oedema or bleeding in the past four (4) weeks and no requirement for steroids or anti-epileptic therapy.
- Cardiac left ventricular function with resting ejection fraction less than 50%
- Absolute neutrophil count (ANC) less than 1500 / mm3.
- Platelets count less than 100 000/mm3.
- Bilirubin more than 1.5 x upper limit of institutional norm.
- Aspartate amino transferase (AST) or alanine amino transferase (ALT) more than 3 x upper limit of institutional norm.
- Serum creatinine more than 1.5 x upper limit of institutional norm.
- Women and men sexually active and unwilling to use a medically acceptable method of contraception.
- Pregnancy or breast-feeding.
- Treatment with other investigational drugs; chemotherapy, immunotherapy, or radiotherapy or participation in another clinical study with anti-cancer therapy within the past 4 weeks before start of therapy or concomitantly with this study.
- Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before start of therapy or concomitantly with this study (2 weeks for trastuzumab).
- Patients unable to comply with the protocol.
- Active alcohol or drug abuse.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00716417
Locations
| Belgium | |
| 1200.37.3202 Boehringer Ingelheim Investigational Site | |
| Bruxelles, Belgium | |
| 1200.37.3201 Boehringer Ingelheim Investigational Site | |
| Edegem, Belgium | |
| 1200.37.3203 Boehringer Ingelheim Investigational Site | |
| Gent, Belgium | |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00716417 History of Changes |
| Other Study ID Numbers: | 1200.37, 2008-002613-43 |
| Study First Received: | July 15, 2008 |
| Last Updated: | January 19, 2012 |
| Health Authority: | Belgium: Federal Agency for Medicines and Health Products |
Additional relevant MeSH terms:
|
Neoplasms Cisplatin Paclitaxel Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Radiation-Sensitizing Agents |
Physiological Effects of Drugs Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Phytogenic |
ClinicalTrials.gov processed this record on May 23, 2013